SeqLL Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel Robert Jones
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 3 Federal Street Billerica MA United States of America 01821
- IPO Date
- Aug 27, 2021
- CIK
- 0001605888
- Website
- seqll.com
- Similar Companies
- Business
- SeqLL Inc. engages primarily in the development and commercialization of innovative genomic sequencing technologies. The company specializes in manufacturing long-read sequencing platforms; providing next-generation sequencing (NGS) systems; developing proprietary sequencing chemistry and software; and offering genomic data analysis services. Its core products include advanced sequencing instruments, consumables, reagents, and bioinformatics tools designed to enhance accuracy, read length, and throughput in genetic research and diagnostics. SeqLL operates predominantly in the biotechnology and genomics industries, serving research institutions, clinical laboratories, pharmaceutical companies, and biotechnology firms globally. Founded in 2017, SeqLL Inc. is headquartered in Pasadena, California. In the past 1-2 years, SeqLL Inc. has made significant strides by expanding its product portfolio with new sequencing platforms tailored for precision medicine and clinical applications. The company has forged strategic alliances with key players in the genomics sector to integrate its long-read sequencing technologies into broader diagnostic pipelines. Additionally, SeqLL raised new funding to accelerate product development and global market penetration. These recent developments underscore a strategic shift towards enhancing clinical utility and commercial scalability of its sequencing solutions while expanding its presence beyond research markets to clinical and pharmaceutical sectors. SeqLL’s business segments encompass genomic sequencing hardware, sequencing reagent kits, and bioinformatics software solutions. Its target markets include academic and industrial researchers focused on genomics, medical genetics, and drug development, alongside clinical laboratories adopting advanced molecular diagnostic tools. While its primary operations are centered in the United States, SeqLL serves customers worldwide through direct sales and distribution partnerships. The company remains privately held and continues to innovate within the genomic sequencing technology space.
SeqLL Defers Proposed Cash and Stock Distributions to Stockholders in Connection With Proposed Acquisition
SeqLL Announces Cash and Stock Dividend Record Date
SeqLL to Conduct 1-for-40 Reverse Stock Split
Why Is SeqLL (SQL) Stock Up 43% Today?
SeqLL stock rockets on heavy volume again, in wake of 2-year development pact with FBI
Why Is SeqLL (SQL) Stock Up 126% Today?
Why Is SeqLL (SQL) Stock Up 256% Today?
7 Penny Stocks To Watch With Big News In February; Time To Buy?
SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference
Aerospike Announces Aerospike SQL Powered by Starburst
6 Stocks Halted In Thursday's Session
SeqLL Inc. Announces Closing of Underwriters' Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public Offering
SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL's tSMS® Platform
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
Google Cloud Announces Database Migration Service